Discovery, chemical biology and early clinical development of NXP800, an activator of GCN2 and the Integrated Stress Response and suppressor of the HSF1 pathway, for ARID1 A mutant ovarian cancer

Dr. Paul Workman
Professor, Centre for Cancer Drug Discovery, The Institute of Cancer Research, London, UK
Thursday, December 12, 2024 - 11:00am
PMH, 610 University Avenue, 6th Floor Auditorium, Rm 6-604
Special Seminar
Host: 
Dr. Cheryl Arrowsmith
OCI Special Seminar